More than one-third of patients with IBD are affected by extraintestinal manifestations or extraintestinal complications beyond the intestinal manifestation of the disease. The most common manifestations include arthropathies, mucocutaneous and ophthalmological manifestations, as well as conditions affecting the hepatobiliary system, both in Crohn's disease and ulcerative colitis. However, less frequent manifestations, such as pulmonary or neurological manifestations, should also be considered in patients with IBD. Several extraintestinal manifestations follow the course of the underlying intestinal activity, whereas others are independent from the intestinal inflammation. Extraintestinal complications such as iron-deficiency anaemia and osteoporosis are consequences of the intestinal disease or of disease-specific treatment. As extraintestinal manifestations and complications strongly influence quality of life, and to avoid severe complications, adequate treatment is mandatory in affected patients. We provide a comprehensive overview of different extraintestinal manifestations and complications, including their management, in patients with IBD.
Extraintestinal symptoms are common in patients with IBD and include extraintestinal manifestations and extraintestinal complications, which can affect nearly every organ
Extraintestinal manifestations include IBD-related diseases that correlate with intestinal disease activity (for example erythema nodosum) and activity-independent diseases such as primary sclerosing cholangitis and ankylosing spondylitis
Extraintestinal complications can be subdivided into those caused by the disease itself and treatment-induced complications
Early recognition and adequate treatment of extraintestinal symptoms is necessary to prevent severe morbidity and mortality in patients with IBD
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
The risk of rheumatoid arthritis among patients with inflammatory bowel disease: a systematic review and meta-analysis
BMC Gastroenterology Open Access 17 June 2020
Pediatric Nephrology Open Access 09 December 2019
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rothfuss, K. S., Stange, E. F. & Herrlinger, K. R. Extraintestinal manifestations and complications in inflammatory bowel diseases. World. J. Gastroenterol. 12, 4819–4831 (2006).
Danese, S. et al. Extraintestinal manifestations in inflammatory bowel disease. World. J. Gastroenterol. 11, 7227–7236 (2005).
Rankin, G. B., Watts, H. D., Melnyk, C. S. & Kelley, M. L. Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77, 914–920 (1979).
Su, C. G., Judge, T. A. & Lichtenstein, G. R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Clin. North Am. 31, 307–327 (2002).
Bernstein, C. N., Blanchard, J. F., Rawsthorne, P. & Yu, N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 96, 1116–1122 (2001).
Lakatos, L. et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J. Gastroenterol. 9, 2300–2307 (2003).
Ricart, E. et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case–control study. Inflamm. Bowel Dis. 10, 207–214 (2004).
Ardizzone, S., Puttini, P. S., Cassinotti, A. & Porro, G. B. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 40 (Suppl. 2), S253–S259 (2008).
Das, K. M. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig. Dis. Sci. 44, 1–13 (1999).
Grant, A. J., Lalor, P. F., Salmi, M., Jalkanen, S. & Adams, D. H. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359, 150–157 (2002).
Salmi, M. & Jalkanen, S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm. Bowel Dis. 4, 149–156 (1998).
Salmi, M. & Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J. Immunol. 166, 4650–4657 (2001).
Satsangi, J., Grootscholten, C., Holt, H. & Jewell, D. P. Clinical patterns of familial inflammatory bowel disease. Gut 38, 738–741 (1996).
Orchard, T. R. et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 118, 274–278 (2000).
Orchard, T. R. et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123, 714–718 (2002).
Mallas E G., Mackintosh, P., Asquith, P. & Cooke, W. T. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut 17, 906–910 (1976).
Roussomoustakaki, M. et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 112, 1845–1853 (1997).
Peeters, H. et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann. Rheum. Dis. 63, 1131–1134 (2004).
Veloso, F. T., Carvalho, J. & Magro, F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J. Clin. Gastroenterol. 23, 29–34 (1996).
Brakenhoff, L. K., van der Heijde, D. M., Hommes, D. W., Huizinga, T. W. & Fidder, H. H. The joint–gut axis in inflammatory bowel diseases. J. Crohns Colitis 4, 257–268 (2010).
Salvarani, C. et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand. J. Gastroenterol. 36, 1307–1313 (2001).
de Vlam, K. et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J. Rheumatol. 27, 2860–2865 (2000).
Palm, O., Bernklev, T., Moum, B. & Gran, J. T. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J. Rheumatol. 32, 1755–1759 (2005).
Palm, O., Moum, B., Jahnsen, J. & Gran, J. T. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 40, 1256–1261 (2001).
Orchard, T. R., Wordsworth, B. P. & Jewell, D. P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42, 387–391 (1998).
Bourikas, L. A. & Papadakis, K. A. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1915–1924 (2009).
Trikudanathan, G., Venkatesh, P. G. & Navaneethan, U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 72, 2333–2349 (2012).
Van Praet, L., Jacques, P., Van den Bosch, F. & Elewaut, D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat. Rev. Rheumatol. 8, 288–295 (2012).
Brown, M. A. Progress in the genetics of ankylosing spondylitis. Brief Funct. Genomics 10, 249–257 (2011).
Mielants, H. et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J. Rheumatol. 22, 2273–2278 (1995).
Brown, M. A. et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann. Rheum. Dis. 55, 268–270 (1996).
Palm, O., Moum, B., Ongre, A. & Gran, J. T. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J. Rheumatol. 29, 511–515 (2002).
Steer, S. et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J. Rheumatol. 30, 518–522 (2003).
Thjodleifsson, B., Geirsson, A. J., Bjornsson, S. & Bjarnason, I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum. 56, 2633–2639 (2007).
Clegg, D. O., Reda, D. J. & Abdellatif, M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 42, 2325–2329 (1999).
Kefalakes, H., Stylianides, T. J., Amanakis, G. & Kolios, G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur. J. Clin. Pharmacol. 65, 963–970 (2009).
Sandborn, W. J. et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin. Gastroenterol. Hepatol. 4, 203–211 (2006).
Reinisch, W. et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment. Pharmacol. Ther. 17, 1371–1380 (2003).
Mahadevan, U., Loftus, E. V. Jr, Tremaine, W. J. & Sandborn, W. J. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 97, 910–914 (2002).
El Miedany, Y., Youssef, S., Ahmed, I. & El Gaafary, M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol. 101, 311–317 (2006).
Clegg, D. O. Treatment of ankylosing spondylitis. J. Rheumatol. Suppl. 78, 24–31 (2006).
Van den Bosch, F., Kruithof, E., De Vos, M., De Keyser, F. & Mielants, H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356, 1821–1822 (2000).
Ellman, M. H., Hanauer, S., Sitrin, M. & Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J. Clin. Rheumatol. 7, 67–71 (2001).
Herfarth, H. et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am. J. Gastroenterol. 97, 2688–2690 (2002).
Generini, S. et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann. Rheum. Dis. 63, 1664–1669 (2004).
Zochling J., van der Heijde, D., Dougados, M. & Braun, J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann. Rheum. Dis. 65, 423–432 (2006).
Lakatos, P. L. et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion 86 (Suppl. 1), 28–35 (2012).
Thrash, B., Patel, M., Shah, K. R., Boland, C. R. & Menter, A. Cutaneous manifestations of gastrointestinal disease: Part II. J. Am. Acad. Dermatol. 68, 211.e1–211.e33 (2013).
Farhi, D. et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 87, 281–293 (2008).
Freeman, H. J. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can. J. Gastroenterol. 19, 603–606 (2005).
Trost, L. B. & McDonnell, J. K. Important cutaneous manifestations of inflammatory bowel disease. Postgrad. Med. J. 81, 580–585 (2005).
Timani, S. & Mutasim, D. F. Skin manifestations of inflammatory bowel disease. Clin. Dermatol. 26, 265–273 (2008).
Juillerat, P. et al. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology 215, 245–251 (2007).
Wollina, U. & Haroske, G. Pyoderma gangraenosum. Curr. Opin. Rheumatol. 23, 50–56 (2011).
Farrell, A. M., Black, M. M., Bracka, A. & Bunker, C. B. Pyoderma gangrenosum of the penis. Br. J. Dermatol. 138, 337–340 (1998).
Lopez San Roman, A. et al. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev. Esp. Enferm. Dig. 96, 420–422 (2004).
Fonder, M. A., Cummins, D. L., Ehst, B. D., Anhalt, G. J. & Meyerle, J. H. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J. Burns Wounds 5, e8 (2006).
Jose, F. A. & Heyman, M. B. Extraintestinal manifestations of inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 46, 124–133 (2008).
Evans, P. E. & Pardi, D. S. Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. MedGenMed 9, 55 (2007).
Mintz, R., Feller, E. R., Bahr, R. L. & Shah, S. A. Ocular manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 10, 135–139 (2004).
Murphy, C. C. et al. Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111, 352–356 (2004).
Navaneethan, U. & Shen, B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1598–1619 (2010).
Pitchumoni, C. S., Rubin, A. & Das, K. Pancreatitis in inflammatory bowel diseases. J. Clin. Gastroenterol. 44, 246–253 (2010).
Broome, U. & Bergquist, A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26, 31–41 (2006).
Venkatesh, P. G., Navaneethan, U. & Shen, B. Hepatobiliary disorders and complications of inflammatory bowel disease. J. Dig. Dis. 12, 245–256 (2011).
Kim, W. R., Ludwig, J. & Lindor, K. D. Variant forms of cholestatic diseases involving small bile ducts in adults. Am. J. Gastroenterol. 95, 1130–1138 (2000).
Joo, M. et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case–control study. Am. J. Surg. Pathol. 33, 854–862 (2009).
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S. & Blackstone, M. O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest. Endosc. 56, 48–54 (2002).
Loftus, E. V. Jr et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54, 91–96 (2005).
Talwalkar, J. A. & Lindor, K. D. Primary sclerosing cholangitis. Inflamm. Bowel Dis. 11, 62–72 (2005).
Lindor, K. D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336, 691–695 (1997).
Eaton, J. E. et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am. J. Gastroenterol. 106, 1638–1645 (2011).
Brink, M. A. et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 116, 1420–1427 (1999).
Damiao, A. et al. Gallbladder hypokinesia in Crohn's disease. Digestion 58, 458–463 (1997).
Pitt, H. A. et al. Increased risk of cholelithiasis with prolonged total parenteral nutrition. Am. J. Surg. 145, 106–112 (1983).
Nathan, D. M., Angus, P. W. & Gibson, P. R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J. Gastroenterol. Hepatol. 21, 1366–1371 (2006).
Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J. & Sands, B. E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7, 874–881 (2009).
Shale, M., Kanfer, E., Panaccione, R. & Ghosh, S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57, 1639–1641 (2008).
Tichelaar, Y. I., Kluin-Nelemans, H. J. & Meijer, K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb. Haemost. 107, 827–837 (2012).
Di Fabio, F., Lykoudis, P. & Gordon, P. H. Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance. Semin. Thromb. Hemost. 37, 220–225 (2011).
Koutroubakis, I. E. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 266–272 (2005).
Tsiolakidou, G. & Koutroubakis, I. E. Thrombosis and inflammatory bowel disease—the role of genetic risk factors. World J. Gastroenterol. 14, 4440–4444 (2008).
Liang, J. et al. Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. J. Gastroenterol. 46, 1158–1166 (2011).
Oussalah, A., Gueant, J. L. & Peyrin-Biroulet, L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 34, 1173–1184 (2011).
Yilmaz, A. et al. Pulmonary involvement in inflammatory bowel disease. World J. Gastroenterol. 16, 4952–4957 (2010).
Betancourt, S. L., Palacio, D., Jimenez, C. A., Martinez, S. & Marom, E. M. Thoracic manifestations of inflammatory bowel disease. AJR Am. J. Roentgenol. 197, W452–W456 (2011).
Basseri, B., Enayati, P., Marchevsky, A. & Papadakis, K. A. Pulmonary manifestations of inflammatory bowel disease: case presentations and review. J. Crohns Colitis 4, 390–397 (2010).
Abu-Hijleh, M., Evans, S. & Aswad, B. Pleuropericarditis in a patient with inflammatory bowel disease: a case presentation and review of the literature. Lung 188, 505–510 (2010).
Pardi, D. S., Tremaine, W. J., Sandborn, W. J. & McCarthy, J. T. Renal and urologic complications of inflammatory bowel disease. Am. J. Gastroenterol. 93, 504–514 (1998).
Oikonomou, K., Kapsoritakis, A., Eleftheriadis, T., Stefanidis, I. & Potamianos, S. Renal manifestations and complications of inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1034–1045 (2011).
Oikonomou, K. A., Kapsoritakis, A. N., Stefanidis, I. & Potamianos, S. P. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron. Clin. Pract. 119, c89–c94 (2011).
Fraser, J. S., Muller, A. F., Smith, D. J., Newman, D. J. & Lamb, E. J. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment. Pharmacol. Ther. 15, 1131–1137 (2001).
Poulou, A. C. et al. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J. Gastroenterol. 12, 739–746 (2006).
Izzedine, H. et al. Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 123, 1436–1440 (2002).
Herrlinger, K. R. et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment. Pharmacol. Ther. 15, 363–369 (2001).
Obici, L. & Merlini, G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med. Wkly 142, w13580 (2012).
Ben-Ami, H. et al. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can. J. Gastroenterol. 16, 225–229 (2002).
McConnell, N., Campbell, S., Gillanders, I., Rolton, H. & Danesh, B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 89, 835–841 (2002).
Kane, S. Urogenital complications of Crohn's disease. Am. J. Gastroenterol. 101 (12 Suppl.), S640–S643 (2006).
Parmar, M. S. Kidney stones. BMJ 328, 1420–1424 (2004).
Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86, 242–251 (2007).
Geissler, A. et al. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 345, 897–898 (1995).
Singh, S., Kumar, N., Loftus, E. V. Jr & Kane, S. V. Neurologic complications in patients with inflammatory bowel disease: Increasing relevance in the era of biologics. Inflamm. Bowel Dis. 19, 864–872 (2012).
Zois, C. D., Katsanos, K. H., Kosmidou, M. & Tsianos, E. V. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J. Crohns Colitis 4, 115–124 (2010).
Bogenrieder, T., Rogler, G., Vogt, T., Landthaler, M. & Stolz, W. Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. Dermatology 206, 273–278 (2003).
Stubgen, J. P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37, 281–292 (2008).
Vadikolias, K. et al. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease. Eur. J. Gastroenterol. Hepatol 19, 159–162 (2007).
Ott, C., Liebold, A., Takses, A., Strauch, U. G. & Obermeier, F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol. Res. Pract. 2012, 595970 (2012).
Voegtlin, M. et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J. Crohns Colitis 4, 642–648 (2010).
Bager, P. et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand. J. Gastroenterol. 46, 304–309 (2011).
Hwang, C., Ross, V. & Mahadevan, U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm. Bowel Dis. 18, 1961–1981 (2012).
Leitgeb, C., Pecherstorfer, M., Fritz, E. & Ludwig, H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73, 2535–2542 (1994).
Gasche, C. et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm. Bowel Dis. 13, 1545–1553 (2007).
Kent, A. J., Blackwell, V. J. & Travis, S. P. What is the optimal treatment for anemia in inflammatory bowel disease? Curr. Drug Deliv. 9, 356–366 (2012).
Glass, G. B. & Mersheimer, W. L. Metabolic turnover of vitamin B12 in the normal and diseased liver. Am. J. Clin. Nutr. 8, 285–292 (1960).
Bjarnason, I. et al. Reduced bone density in patients with inflammatory bowel disease. Gut 40, 228–233 (1997).
Pigot, F. et al. Low bone mineral density in patients with inflammatory bowel disease. Dig. Dis. Sci. 37, 1396–1403 (1992).
Compston, J. E. et al. Osteoporosis in patients with inflammatory bowel disease. Gut 28, 410–415 (1987).
Bernstein, C. N., Leslie, W. D. & Leboff, M. S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124, 795–841 (2003).
Bernstein, C. N., Blanchard, J. F., Leslie, W., Wajda, A. & Yu, B. N. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann. Intern. Med. 133, 795–799 (2000).
Vestergaard, P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med. 95, 469–480 (2004).
[No authors listed] American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 124, 791–794 (2003).
Reid, D. M. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006–1013 (2000).
Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292–299 (1998).
The authors declare no competing financial interests.
About this article
Cite this article
Ott, C., Schölmerich, J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10, 585–595 (2013). https://doi.org/10.1038/nrgastro.2013.117
This article is cited by
Nature Reviews Gastroenterology & Hepatology (2022)
Ironing It All Out: A Comprehensive Review of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences (2022)
Phytochemistry Reviews (2022)
Journal of Gastroenterology (2022)
Nature Reviews Gastroenterology & Hepatology (2021)